SCHEMBL9975962

SCHEMBL9975962

COc1ccc(/C=C/c2cc(=O)c3ccccc3o2)cc1

nearest known ligand 0.80

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 6/20 0.80
ALDH1A1 P00352 5/20 0.80
HPGD P15428 5/20 0.80
KDM4E B2RXH2 4/20 0.80
NPC1 O15118 5/20 0.72
RAB9A P51151 5/20 0.72
SMN1; SMN2 Q16637 4/20 0.72
NPSR1 Q6W5P4 1/20 0.72
MAOB P27338 3/20 0.67
MAOA P21397 3/20 0.67
MEN1 O00255 2/20 0.60
KMT2A Q03164 2/20 0.60
MAPK1 P28482 1/20 0.60
TP53 P04637 3/20 0.59
HSD17B10 Q99714 2/20 0.59
CASP1 P29466 1/20 0.59
CASP7 P55210 1/20 0.59
CYP3A4 P08684 2/20 0.59
TNKS O95271 2/20 0.59
LMNA P02545 1/20 0.59

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9975964 0.89 MAPT (0.68) MAPTALDH1A1HPGDKDM4ENPC1
SCHEMBL9975963 0.87 KDM4E (0.68) MAPTALDH1A1HPGDKDM4ENPC1
SCHEMBL9975959 0.84 KDM4E (0.64) MAPTALDH1A1HPGDKDM4ENPC1
SCHEMBL11823788 0.84 KDM4E (0.64) MAPTALDH1A1HPGDKDM4ENPC1
SCHEMBL2465240 0.84 HPGD (1.00) MAPTALDH1A1HPGDKDM4ENPC1
SCHEMBL435366 0.84 HPGD (1.00) MAPTALDH1A1HPGDKDM4ENPC1
SCHEMBL9976017 0.83 MAPT (0.67) MAPTALDH1A1HPGDKDM4ENPC1
SCHEMBL9976005 0.82 KDM4E (0.78) MAPTALDH1A1HPGDKDM4ENPC1
SCHEMBL9976007 0.82 KDM4E (0.78) MAPTALDH1A1HPGDKDM4ENPC1
SCHEMBL9976042 0.82 KDM4E (0.64) MAPTALDH1A1HPGDKDM4ENPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8546397-B2 DNA methylation inhibitors THE OHIO STATE UNIVERSITY RESEARCH FOUNDATION (US) 2013-10-01 US disclosed
US-8546397-B2 DNA methylation inhibitors THE OHIO STATE UNIVERSITY RESEARCH FOUNDATION (US) 2013-10-01 US disclosed
WO-2012087889-A2 DNA METHYLATION INHIBITORS THE OHIO STATE UNIVERSITY RESEARCH FOUNDATION (US) 2012-06-28 WO disclosed
US-20120157465-A1 DNA METHYLATION INHIBITORS THE OHIO STATE UNIVERSITY RESEARCH FOUNDATION (US) 2012-06-21 US disclosed
US-20120157465-A1 DNA METHYLATION INHIBITORS THE OHIO STATE UNIVERSITY RESEARCH FOUNDATION (US) 2012-06-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120157465-A1 DNA METHYLATION INHIBITORS MECP2, DNMT1, DNMT3B MAPT 3677/4885ALDH1A1 2789/4885HPGD 1457/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.